GenVec, Inc. (Nasdaq:GNVC), Gaithersburg, Md., has announced that
results from multiple ongoing clinical trials utilizing its adenovector
vaccine technologies were presented at the AIDS Vaccine 2007 Conference.
The trials, which are investigating a DNA prime-adenoviral vector boost
strategy, incorporate a multiclade rAd5 HIV- 1 vaccine developed by
GenVec in collaboration with the Vaccine Research Center
("VRC"), National Institute of Allergy and Infectious
Diseases, National Institutes of Health ("NIH").
Dr. Richard Koup of the VRC, delivered an oral presentation,
"Update on Safety and Immunogenicity of VRC Products,"
summarizing data from several ongoing studies sponsored by the
NIH's HIV Vaccine Trials Network ("HTVN"), the
International AIDS Vaccine Initiative ("IAVI") and the U.S.
Military HIV Research Program ("USMHRP") using the DNA
prime-boost regimen. Dr. Koup characterized a strong vaccine induced
cytotoxic (CD8+) T-cell response targeting HIV-infected cells,
confirming the underlying concept of this vaccine. In the TRIAD Phase II
trial, immunogenicity was achieved in approximately seventy percent of
the vaccinated population. Importantly, the effect of pre-existing Ad5
immunity on immunogenicity of the vaccine appeared to be small. More
than ten abstracts, posters, and presentations were presented by the VRC
and its collaborators at this conference.
"The Phase 2 trials have generated a tremendous amount of
information on clinical application of adenovirus vectors as vaccines.
These data strongly support the use of GenVec adenovirus vectors as
vaccines for HIV and other diseases," commented Dr. Rick King,
GenVec's Senior VP of Research.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel
therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM)
is currently in a pivotal clinical study (PACT) in locally advanced
pancreatic cancer. Additional clinical trials are in progress in rectal
cancer, head and neck cancer and melanoma. GenVec also uses its
proprietary adenovector technology to develop vaccines for infectious
diseases including HIV, malaria, foot-and-mouth disease, respiratory
syncytial virus (RSV), and influenza.
For more information, visit http://www.genvec.com or call
240/632-5511.
COPYRIGHT 2007 Worldwide
Videotex Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2007, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.